Home/Products /palbociclib-125-mg-capsule

Palbocare Capsule: Palbociclib 125 mg - Oral Targeted Oncology Therapy

Name: Palbocare 125 mg: Palbociclib Capsule
Brand: Palbocare Capsule
Rating: 4.8 (150 reviews)

Mechanism of Action: Selective CDK 4/6 Inhibition in Breast Cancer

Key Indication: Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Regimens

Combination Therapy: Used with Aromatase Inhibitors or Fulvestrant

Ensuring Patient Adherence and Monitoring in Chronic Oral Oncology Treatment

Secure Your Monopoly: Palbocare PCD Pharma Franchise in High-Value Targeted Oncology

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Stimulant

Urology

Endocrine therapy and Palbociclib combination

Palbocare Capsule (Palbociclib 125 mg) Combination Dosing Guide PDF

Palbocare Capsule

Composition : Palbociclib 125 mg Capsule

Dosage Form : Capsule

Packaging Type : in a Bottle

Packaging : 21 Capsules

Price : ₹0/-

Please Contact For Best Price

Palbocare Capsule (Palbociclib ) is a critical oral medication in modern oncology, belonging to the class of Cyclin-Dependent Kinase () Inhibitors. It is the standard cornerstone treatment for patients with Hormone Receptor-Positive (), HER2-Negative advanced or metastatic breast cancer.

Mechanism and Impact:Palbociclib works by selectively and reversibly inhibiting $CDK 4$ and $CDK 6$ proteins. This action arrests the cancer cells in the G1 phase of the cell cycle, preventing uncontrolled proliferation. When used in combination with endocrine therapy, it significantly delays disease progression and extends life.

We offer an exclusive PCD Pharma Franchise opportunity for Palbocare Capsule, enabling partners to dominate the premium oral targeted oncology segment.

About the Product

We offer an exclusive PCD Pharma Franchise opportunity for Palbocare Capsule, enabling partners to dominate the premium oral targeted oncology segment.

Hair loss (alopecia) Nausea, vomiting, diarrhea Low blood counts (anemia, leukopenia) Peripheral neuropathy (tingling or numbness) Joint/muscle pain

Metastatic breast cancer Advanced ovarian carcinoma Non-small cell lung cancer (NSCLC) AIDS-related Kaposi’s sarcoma Often used as first-line or second-line therapy, either alone or in combination with other chemotherapeutic agents like cisplatin.

Administered intravenously by trained professionals in a clinical setting. Premedication with corticosteroids, antihistamines, and H2 antagonists is essential to minimize hypersensitivity reactions. Requires close monitoring of blood counts, liver function, and cardiac status.

Store below 25°C, protected from light. Do not freeze. Shake well before use. Keep out of reach of children.